Results 11 to 20 of about 852,629 (213)
Immunological Medicine, 2023 Among various tyrosine kinases, a family of Janus kinases (JAK) has been elucidated as key players in signal transduction from vital cytokine receptors, such as interleukins and interferons.
Hideto Kameda
doaj +3 more sources
The JAK-STAT Pathway and the JAK Inhibitors [PDF]
Journal of Clinical Research in Dermatology, 2020 Dozens of cytokines that bind Type I and Type II receptors use the Janus Kinases (JAK) and the Signal Transducer and Activator of Transcription (STAT) proteins pathway for intracellular signaling, orchestrating hematopoiesis, inducing inflammation, and controlling the immune response.
Ana Paula Galli Sanchez +2 more
openaire +1 more source
JAK-STAT, 2013 The endocrine cytokine leptin is mainly secreted by white adipose tissue and plasma leptin levels positively correlate with body fat mass. Via its action on neurons in the hypothalamic arcuate nucleus (ARC), leptin regulates body weight by stimulating energy expenditure and inhibiting food intake.
Peelman, Frank, Tavernier, Jan
openaire +2 more sources
The JAK–STAT pathway in keloid pathogenesis: a systematic review with qualitative synthesis
Experimental Dermatology, Volume 32, Issue 5, Page 588-598, May 2023., 2023 Abstract Keloid tissues contain inflammatory cells and upregulated pro‐inflammatory cytokines. The Janus kinase (JAK)‐signal transducer and activator of transcription (STAT) pathway mediate cellular responses to these cytokines. We performed a systematic review on the role of the JAK–STAT pathway in keloid pathogenesis and the evidence for JAK–STAT ...
Qi Yin +5 more
wiley +1 more source
STAT3 and REDD1: an unconventional story of gene repression
The FEBS Journal, Volume 290, Issue 7, Page 1735-1739, April 2023., 2023 Compared with the canonical mechanisms of activating gene expression, the non‐canonical actions of the transcription factor STAT3 have not received much attention. Köhler et al. highlight a novel mechanism of STAT3 repression over the REDD1 gene. These results are essential for understanding the role of the REDD1 protein and the effects of this precise
Pol Garcia‐Segura, Cristina Malagelada
wiley +1 more source
Clinical and Translational Medicine, Volume 12, Issue 8, August 2022., 2022 Activated JAK‐STAT signalling cascade plays a critical role in the onset of therapy‐ and castration‐resistant disease that is associated with stem cell plasticity. IFIT5, a downstream effector of JAK‐STAT signalling pathway, exhibits a new functional role in modulating stemness transcriptional factors (such as BMI1, NANOG and SOX2) by promoting ...
U‐Ging Lo +10 more
wiley +1 more source
eJHaem, Volume 3, Issue 3, Page 764-774, August 2022., 2022 Abstract Inhibitors of the Bromo‐ and Extra‐Terminal domain (BET) family proteins have strong preclinical antitumor activity in multiple tumor models, including lymphomas. Limited single‐agent activity has been reported in the clinical setting. Here, we have performed a pharmacological screening to identify compounds that can increase the antitumor ...
Filippo Spriano +14 more
wiley +1 more source
IFN‐α/β‐mediated NK2R expression is related to the malignancy of colon cancer cells
Cancer Science, Volume 113, Issue 8, Page 2513-2525, August 2022., 2022 IFN‐α/β induced neurokinin 2 receptor (NK2R), a G protein‐coupled receptor for neurokinin A in a JAK1/2‐dependent manner. NK2R expression was related to the tumorigeneis and mietastatic colonization of colon cancer cells. Therefore, NK2R blockade will be a promising strategy for colon cancers.
Huihui Xiang +13 more
wiley +1 more source
British Journal of Haematology, Volume 198, Issue 2, Page 317-327, July 2022., 2022 Summary Fedratinib, an oral Janus kinase‐2 (JAK2) inhibitor, is approved for patients with myelofibrosis (MF) and platelet counts ≥50 × 109/l, based on outcomes from the phase 3, placebo‐controlled JAKARTA trial in JAK‐inhibitor‐naïve MF, and the phase 2, single‐arm JAKARTA2 trial in patients previously treated with ruxolitinib.
Claire N. Harrison +11 more
wiley +1 more source
C/EBPβ regulates the JAK/STAT signaling pathway in triple‐negative breast cancer
FEBS Open Bio, Volume 11, Issue 4, Page 1250-1258, April 2021., 2021 C/EBPβ is a b‐ZIP transcription factor. Here, we present evidence that C/EBPβ is specifically overexpressed in human TNBC samples, but not in non‐TNBC samples. C/EBPβ depletion dramatically suppresses TNBC cell growth, migration, invasion, and colony formation ability.
Shu Wang +7 more
wiley +1 more source